BRIEFING

 Cefazolin for Injection. This proposal is based on the version of the monograph official as of August 1, 2023. It is proposed to revise the monograph with the following changes:

1. Replace the use of 197U in Identification A with the UV spectra agreement from the Assay. Additionally, revise the Detector in the Assay to support the proposed Identification A.

2. In the Assay:

   • Update Buffer A and Buffer B preparations, including removal of the pH requirement, to align with other cefazolin family monographs.

   • Remove the use of the Internal standard solution throughout the test, and revise the definition of C_S to align with the current label of USP Cefazolin RS.

   • Update the Acceptance criteria to accommodate the proposed changes to the test for Uniformity of Dosage Units.

   • Correct the diameter of the HPLC column based on the supporting data.

   • Remove the Resolution and Column efficiency requirements because the remaining Suitability requirements are sufficient to determine System suitability.

3. Delete the Procedure for content uniformity from Uniformity of Dosage Units test to allow for flexibility.

4. Replace the use of a numerical acceptance limit with “Meets the requirements” in the Bacterial Endotoxins Test to align with the general chapter.

5. In Sterility Tests, remove the reference to the membrane filtration technique to allow for flexibility.

6. In the tests for Optical Rotation and pH, clarify the Sample solution preparations.

7. Add temperature and light protection requirements in the Packaging and Storage section based on the approved drug product inserts.

Additionally, minor editorial changes have been made to update the monograph to current USP style.

 (SM1: F. Gu)

 Case ID—SUB-1650